MNOV vs. RLYB, VHAQ, CELU, LTRN, EGRX, MURA, LABP, ANEB, IMMX, and HCWB
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Rallybio (RLYB), Viveon Health Acquisition (VHAQ), Celularity (CELU), Lantern Pharma (LTRN), Eagle Pharmaceuticals (EGRX), Mural Oncology (MURA), Landos Biopharma (LABP), Anebulo Pharmaceuticals (ANEB), Immix Biopharma (IMMX), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
MediciNova (NASDAQ:MNOV) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
MediciNova has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.64, indicating that its stock price is 264% less volatile than the S&P 500.
Rallybio has a consensus price target of $12.20, indicating a potential upside of 617.65%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than MediciNova.
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 16.9% of MediciNova shares are owned by insiders. Comparatively, 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, MediciNova and MediciNova both had 3 articles in the media. MediciNova's average media sentiment score of 0.80 beat Rallybio's score of 0.01 indicating that MediciNova is being referred to more favorably in the media.
MediciNova has higher revenue and earnings than Rallybio. MediciNova is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
MediciNova's return on equity of -13.19% beat Rallybio's return on equity.
MediciNova received 177 more outperform votes than Rallybio when rated by MarketBeat users. However, 74.42% of users gave Rallybio an outperform vote while only 52.38% of users gave MediciNova an outperform vote.
Summary
MediciNova beats Rallybio on 9 of the 14 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
